{"id":543,"date":"2024-05-18T21:16:16","date_gmt":"2024-05-18T21:16:16","guid":{"rendered":"https:\/\/www.neolyspharma.ca\/nouvelles\/"},"modified":"2024-07-23T08:17:41","modified_gmt":"2024-07-23T08:17:41","slug":"news","status":"publish","type":"page","link":"https:\/\/neolyspharma.ca\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"news.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-543","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neolys Pharma News | Funding and Partnerships<\/title>\n<meta name=\"description\" content=\"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neolyspharma.ca\/en\/news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neolys Pharma News | Funding and Partnerships\" \/>\n<meta property=\"og:description\" content=\"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neolyspharma.ca\/en\/news\/\" \/>\n<meta property=\"og:site_name\" content=\"Neolyspharma\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-23T08:17:41+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/\",\"name\":\"Neolys Pharma News | Funding and Partnerships\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\"},\"datePublished\":\"2024-05-18T21:16:16+00:00\",\"dateModified\":\"2024-07-23T08:17:41+00:00\",\"description\":\"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"name\":\"Neolys Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\"},\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\",\"name\":\"Neolys Pharma inc.\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"contentUrl\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"width\":512,\"height\":242,\"caption\":\"Neolys Pharma inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neolys-pharma\"],\"legalName\":\"Neolys Pharma inc.\",\"telephone\":\"+1-418-931-2195\",\"email\":\"info@neolyspharma.ca\",\"description\":\"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neolys Pharma News | Funding and Partnerships","description":"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neolyspharma.ca\/en\/news\/","og_locale":"en_US","og_type":"article","og_title":"Neolys Pharma News | Funding and Partnerships","og_description":"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.","og_url":"https:\/\/neolyspharma.ca\/en\/news\/","og_site_name":"Neolyspharma","article_modified_time":"2024-07-23T08:17:41+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neolyspharma.ca\/en\/news\/","url":"https:\/\/neolyspharma.ca\/en\/news\/","name":"Neolys Pharma News | Funding and Partnerships","isPartOf":{"@id":"https:\/\/neolyspharma.ca\/en\/#website"},"datePublished":"2024-05-18T21:16:16+00:00","dateModified":"2024-07-23T08:17:41+00:00","description":"Announcements from Neolys Pharma: funding secured, licensing agreements and progress on aminosteroid derivatives.","breadcrumb":{"@id":"https:\/\/neolyspharma.ca\/en\/news\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neolyspharma.ca\/en\/news\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neolyspharma.ca\/en\/news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neolyspharma.ca\/en\/"},{"@type":"ListItem","position":2,"name":"News"}]},{"@type":"WebSite","@id":"https:\/\/neolyspharma.ca\/en\/#website","url":"https:\/\/neolyspharma.ca\/en\/","name":"Neolys Pharma","description":"","publisher":{"@id":"https:\/\/neolyspharma.ca\/en\/#organization"},"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/neolyspharma.ca\/en\/#organization","name":"Neolys Pharma inc.","url":"https:\/\/neolyspharma.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","contentUrl":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","width":512,"height":242,"caption":"Neolys Pharma inc."},"image":{"@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neolys-pharma"],"legalName":"Neolys Pharma inc.","telephone":"+1-418-931-2195","email":"info@neolyspharma.ca","description":"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers."}]}},"_links":{"self":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/pages\/543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/comments?post=543"}],"version-history":[{"count":1,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/pages\/543\/revisions"}],"predecessor-version":[{"id":547,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/pages\/543\/revisions\/547"}],"wp:attachment":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/media?parent=543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}